Published in J Cell Physiol on July 01, 2005
Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2011) 1.65
Urokinase and its receptors in chronic kidney disease. Front Biosci (2008) 0.94
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem (2011) 0.88
Interaction of late apoptotic and necrotic cells with vitronectin. PLoS One (2011) 0.83
Urokinase receptor counteracts vascular smooth muscle cell functional changes induced by surface topography. Theranostics (2013) 0.76
Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab (2006) 6.44
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med (2008) 2.54
PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A (2009) 2.38
TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism. J Biol Chem (2002) 2.35
Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology (2007) 2.22
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood (2013) 2.14
Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol (2002) 2.03
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest (2009) 1.96
Increased in-stent stenosis in ApoE knockout mice: insights from a novel mouse model of balloon angioplasty and stenting. Arterioscler Thromb Vasc Biol (2007) 1.89
Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A (2005) 1.84
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res (2003) 1.81
Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol (2007) 1.78
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest (2011) 1.63
Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest (2009) 1.63
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet (2007) 1.57
Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med (2010) 1.54
NF-κB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat Immunol (2012) 1.48
Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2006) 1.48
MafB is essential for renal development and F4/80 expression in macrophages. Mol Cell Biol (2006) 1.48
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 1.45
Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem (2003) 1.43
Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med (2008) 1.43
The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol (2004) 1.41
Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation (2003) 1.40
Genomic structures of the human and murine corin genes and functional GATA elements in their promoters. J Biol Chem (2002) 1.37
deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol (2005) 1.33
Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood (2008) 1.31
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis (2009) 1.31
Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol (2012) 1.29
Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem (2003) 1.27
CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. Pharmacol Rev (2013) 1.27
Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation (2005) 1.24
Chapter 17. Zymosan-induced peritonitis as a simple experimental system for the study of inflammation. Methods Enzymol (2009) 1.24
Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem (2003) 1.22
Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem (2002) 1.21
Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem (2002) 1.20
17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2003) 1.20
Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med (2005) 1.18
Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol (2007) 1.18
Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol (2002) 1.18
Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur J Immunol (2011) 1.16
Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. Gastroenterology (2009) 1.16
Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol Biol (2006) 1.15
The duffy antigen/receptor for chemokines exists in an oligomeric form in living cells and functionally antagonizes CCR5 signaling through hetero-oligomerization. Mol Pharmacol (2008) 1.14
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest (2002) 1.13
Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation (2004) 1.12
Cell-type-specific expression of the human CD68 gene is associated with changes in Pol II phosphorylation and short-range intrachromosomal gene looping. Genomics (2007) 1.12
Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol (2012) 1.12
Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res (2009) 1.11
Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol (2005) 1.10
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem (2008) 1.08
Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol (2010) 1.08
Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum (2009) 1.07
TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Eur J Immunol (2011) 1.04
Multiple Ets factors and interferon regulatory factor-4 modulate CD68 expression in a cell type-specific manner. J Biol Chem (2003) 1.03
Rev-erbalpha upregulates NF-kappaB-responsive genes in vascular smooth muscle cells. FEBS Lett (2004) 1.03
Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet (2008) 1.02
Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci (Lond) (2010) 1.00
Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 0.99
Efficacy of a novel class of RNA interference therapeutic agents. PLoS One (2012) 0.99
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol (2007) 0.99
Chemerin peptides promote phagocytosis in a ChemR23- and Syk-dependent manner. J Immunol (2010) 0.99
Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. J Mol Histol (2011) 0.99
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery (2010) 0.97
A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract (2009) 0.97
CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis. Circulation (2008) 0.96
HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α-induced excessive erythropoiesis. Blood (2012) 0.95
CCL11 blocks IL-4 and GM-CSF signaling in hematopoietic cells and hinders dendritic cell differentiation via suppressor of cytokine signaling expression. J Leukoc Biol (2008) 0.94
A model of the acid sphingomyelinase phosphoesterase domain based on its remote structural homolog purple acid phosphatase. Protein Sci (2004) 0.91
Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem (2011) 0.91
Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention? J Innate Immun (2012) 0.90
Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res (2004) 0.90
Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo. Immunobiology (2003) 0.90
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A (2013) 0.90
Immunophenotyping of macrophages in human pulmonary tuberculosis and sarcoidosis. Int J Exp Pathol (2003) 0.89
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol (2008) 0.89
RORalpha1 and RORalpha4 suppress TNF-alpha-induced VCAM-1 and ICAM-1 expression in human endothelial cells. FEBS Lett (2004) 0.88
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem (2012) 0.88
Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade. Mol Pharmacol (2011) 0.88
Differential role of regulatory T cells in early and late stages of pulmonary fibrosis. Immunobiology (2012) 0.88
Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. Am J Respir Cell Mol Biol (2011) 0.87
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol (2007) 0.87
Microfluidic impedance cytometer for platelet analysis. Lab Chip (2013) 0.87
Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J Biol Chem (2011) 0.86
Overproduction of acyloxyacyl hydrolase by macrophages and dendritic cells prevents prolonged reactions to bacterial lipopolysaccharide in vivo. J Infect Dis (2009) 0.86
Membrane-bound CC chemokine inhibitor 35K provides localized inhibition of CC chemokine activity in vitro and in vivo. J Immunol (2006) 0.85
Functional analysis of the murine Emr1 promoter identifies a novel purine-rich regulatory motif required for high-level gene expression in macrophages. Genomics (2004) 0.85
Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. Biochem Biophys Res Commun (2011) 0.85
Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol (2010) 0.85
A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost (2007) 0.85
Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. J Neurotrauma (2004) 0.84
Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice. Atherosclerosis (2003) 0.84